Skip to main content

Hormone Replacement Therapy Market to Garner Brimming Revenues by 2018 to 2028

The purpose of this comprehensive forecast report presented by FactMR is to elaborate the various market projections impacting the global hormone replacement therapy market during the period through 2018-2028. This assessment delivers high-end statistics concerning market size, growth in trends and revenue share (US& Mn) linked to different geographies and segmentation types. Readers can acquire precise insights about market growth trends along with upcoming opportunities that are expected to reshape the overall structure of the hormone replacement therapy market during the forecast period.
Request for a Free Sample Report of Concerned Market – https://www.factmr.com/connectus/sample?flag=S&rep_id=2224
The hormone replacement therapy market is a fragmented landscape with presence of few tier one companies and upcoming players. Top five companies involved in the hormone replacement therapy formulations account for a significant share of the overall hormone replacement therapy market. Top 5 players – Novo Nordisk, Pfizer Inc., Janssen NV (a Johnson & Johnson company), Novartis AG and Bayer AG collectively – collectively account for 35 percent revenue share of the hormone replacement therapy market from on the global front. Tier 1 hormone replacement therapy companies are focused on carrying out clinical trials for new product development (NPD). Moreover, these companies are adopting vertical, horizontal and backward integration in a bid to achieve rapid expansion and pace in technological development.
In addition, tier 1 hormone replacement therapy companies are forming alliances to co-develop and commercialize hormone replacement therapy drugs. For instance, Pfizer Inc., and Merck KGaA have formed a strategic alliance to develop avelumab (BAVENCIO) to manage hypothyroidism and other thyroid disorders.
Agreement between FDA and NASEM to Impact Hormone Replacement Therapy Market Growth
Food and Drug Administration (FDA) has signed an agreement with NASEM (National Academies of Science, Engineering & Medicine) and is carrying out expanded agreements with University of Maryland and Johns Hopkins University Centers for Regulatory Science and Innovation. Main focus behind this initiative was to conduct research and inform consumers regarding compounded drugs.
NASEM is examining the utility of treating individuals with compounded BHRT (Bioidentical Hormone Replacement Therapy) products. Compounded Bioidentical hormone replacement therapy products such as testosterone and progesterone are used instead of FDA approved hormone replacement therapy drugs as BHRT drugs are considered more safe and natural for patients. This factor is likely to impact the clinical trials of new hormone replacement therapy products in turn challenging the growth of hormone replacement therapy market.
Affordability has always remained a major challenge for any pharmaceutical drug or formulation. Moreover, insufficient healthcare reimbursements have resulted in individuals opting for cheaper drugs with unclear drug effectiveness. This prompted manufactures of hormone replacement therapy drugs to produce generic versions of the formulations in a bid to bridge the gap between purchasing power of people and hormone replacement therapy drug pricing. Companies developing generic hormone replacement therapy drugs are also acquiring FDA approvals, which is direct inference apropos to drug effectiveness. For instance, Teva pharmaceuticals has introduced generic version of Estrace cream and estradiol vaginal cream in 2018. The trend is expected to auger well for the overall growth of the hormone replacement therapy market.
Rising Prevalence of Osteoporosis to Influence Hormone Replacement Therapy Demand
Growing life expectancy is closely associated with degeneration that further translates into osteoporotic fractures. In addition, this condition further results in an increase in gap between spine bones during menopause with diminishing estrogen levels. According to the International Osteoporosis Foundation, osteoporosis causes over 8.9 million fractures annually on the global front and is likely to grow in the coming years. Rising prevalence of osteoporosis among women is expected to trigger the demand for hormone replacement therapy.
Hormone Replacement Therapy Associated with Reduced Dementia – Key Growth Propellant  
Hormone replacement therapy can protect memory which is required to carry out short-term cognitive tasks after menopausal stress. Estrogen-only hormone replacement therapy can facilitate lower stress levels without impacting memory. In addition, hormone replacement therapy also reduces possibilities of both vascular dementia and Alzheimer’s disease.  
Labels:

Comments

Post a Comment

Popular posts from this blog

Electrosurgery Devices Market: Radiofrequency Electrosurgery Devices will Remain the Top-Selling Product

On the back of rising ageing population, increased instances of surgical procedures and technological innovations, the market for electrosurgical devices is likely to slate lucrative growth triggers in the coming years. Significant spike in surgical procedures pertaining neurology, cardiology, gynecology, and several other general surgeries, electrosurgery devices market is in the cusp of exponential growth. Owing to technological innovations the electrosurgery market in North America has demonstrated growth traction over the years. However, increased healthcare spending towards minimally invasive treatment in Asia-Pacific region is expected to propel the market forward, thus contributing as one of the fastest regional hub in electrosurgery devices market. However, factors such as significant product recalls owing to incompliance with FDA framework remain potential challenges for the growth trajectory. Get sample of this report at https://www.factmr.com/connectus/sample?flag=S...
Post a Comment
Read more

North America to Maintain its Leader Status for the Dermatology Devices Market

 Increasing geriatric population across the world have propelled the demand for the dermatology devices, which in turn has contributed to the growth of the dermatology devices market. Rising adoption of dermatology devices in parallel to the rapid adoption of technology in the dermatology clinics and hospitals for treating skin disorders have been prominent factors for the growth of dermatology devices market. Spur in the spending capability of consumers have facilitated the access to these devices. Pervasiveness of skin disorders has been rising at the global level, which has created demand for acute treatment devices. Developments in the treatment methodologies such as liposuction devices and laser instruments have been successful in attracting the attention of the consumers. A recent report published by Fact.MR states that the global dermatology devices market is anticipated to surpass the whopping value of US$ 1,000 Mn by 2022. Browse Full Report with TOC 'https://www.factm...
Post a Comment
Read more

Lithotripsy Devices Market: Non-Invasive ESWL Witnessing Immense Traction

The report offers a crisp overview of the lithotripsy devices market, which includes an introduction to the lithotripsy devices market in tandem with a definition of the target product – lithotripsy devices. A systematic breakdown of the lithotripsy devices market has been offered in this chapter, which implies scope of the research involved. Size of lithotripsy devices market has been studied in terms of volume (tons) and value (MN), and forecast on the lithotripsy devices market has been offered for the period between 2018 and 2026. The lithotripsy devices market is projected to continue its steady growth due to the burgeoning cases of kidney stones, coupled with the surging demand for minimally invasive medical treatments. According to Fact.MR report, the  lithotripsy devices market  is anticipated to accelerate at 4.3% CAGR during 2018-2026 to reach a value of US$ 1,095.2 MN by the end of 2026. In recent past, lithotripsy has become the most pref...
Post a Comment
Read more